{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:20:08Z","timestamp":1720138808104},"reference-count":67,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,4]]},"DOI":"10.7759\/cureus.63796","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T07:57:12Z","timestamp":1720079832000},"source":"Crossref","is-referenced-by-count":0,"title":["Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Cardiovascular Outcomes: A Review of Literature"],"prefix":"10.7759","author":[{"given":"Sweatha","family":"Mani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abirami","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keerthana","family":"Veluswami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudipta","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailesh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"34 Suppl 1","author":"American Diabetes Association","year":"2011","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011, 34 Suppl 1:S62-9. 10.2337\/dc11-S062","journal-title":"Diabetes Care"},{"key":"ref2","article-title":"Idf diabetes atlas","author":"International Diabetes Federation","year":"2017","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, Eighth Edition 2017. International Diabetes Federation, Brussels, Belgium; 2017. https:\/\/diabetesatlas.org\/upload\/resources\/previous\/files\/8\/IDF_DA_8e-EN-final.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.01.044","article-title":"Risk factor control for coronary artery disease secondary prevention in large randomized trials","volume":"61","author":"Farkouh ME","year":"2013","unstructured":"Farkouh ME, Boden WE, Bittner V, et al.. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol. 2013, 61:1607-15. 10.1016\/j.jacc.2013.01.044","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.335","article-title":"Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes","volume":"291","author":"Saydah SH","year":"2004","unstructured":"Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004, 291:335-42. 10.1001\/jama.291.3.335","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar N","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, et al.. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010, 375:2215-22. 10.1016\/S0140-6736(10)60484-9","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh TA","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022, 24:4-131. 10.1002\/ejhf.2333","journal-title":"Eur J Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2174\/138920011796504509","article-title":"Kidney in diabetes: from organ damage target to therapeutic target","volume":"12","author":"Salvatore T","year":"2011","unstructured":"Salvatore T, Carbonara O, Cozzolino D, Torella R, Nasti R, Lascar N, Sasso FC. Kidney in diabetes: from organ damage target to therapeutic target. Curr Drug Metab. 2011, 12:658-66. 10.2174\/138920011796504509","journal-title":"Curr Drug Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo RA","year":"2013","unstructured":"DeFronzo RA, Hompesch M, Kasichayanula S, et al.. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013, 36:3169-76. 10.2337\/dc13-0387","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-10038-w","article-title":"SGLT2-inhibitors; more than just glycosuria and diuresis","volume":"26","author":"Fathi A","year":"2021","unstructured":"Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev. 2021, 26:623-42. 10.1007\/s10741-020-10038-w","journal-title":"Heart Fail Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer A","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits. Diabetologia. 2017, 60:568-73. 10.1007\/s00125-016-4134-x","journal-title":"Diabetologia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-014-2262-5","article-title":"Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats","volume":"400","author":"Hamouda NN","year":"2015","unstructured":"Hamouda NN, Sydorenko V, Qureshi MA, Alkaabi JM, Oz M, Howarth FC. Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats. Mol Cell Biochem. 2015, 400:57-68. 10.1007\/s11010-014-2262-5","journal-title":"Mol Cell Biochem"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma S","year":"2018","unstructured":"Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018, 61:2108-17. 10.1007\/s00125-018-4670-7","journal-title":"Diabetologia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.05.013","article-title":"Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms","volume":"120","author":"Staels B","year":"2017","unstructured":"Staels B. Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Cardiol. 2017, 120:S28-36. 10.1016\/j.amjcard.2017.05.013","journal-title":"Am J Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1708","article-title":"Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure","volume":"22","author":"Butler J","year":"2020","unstructured":"Butler J, Handelsman Y, Bakris G, Verma S. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. Eur J Heart Fail. 2020, 22:604-17. 10.1002\/ejhf.1708","journal-title":"Eur J Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1581971","article-title":"SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses","volume":"131","author":"Filippatos TD","year":"2019","unstructured":"Filippatos TD, Liontos A, Papakitsou I, Elisaf MS. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019, 131:82-8. 10.1080\/00325481.2019.1581971","journal-title":"Postgrad Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013389","article-title":"SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects","volume":"8","author":"Lam CS","year":"2019","unstructured":"Lam CS, Chandramouli C, Ahooja V, Verma S. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. J Am Heart Assoc. 2019, 8:e013389. 10.1161\/JAHA.119.013389","journal-title":"J Am Heart Assoc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.0898","article-title":"Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure","volume":"5","author":"Bassi NS","year":"2020","unstructured":"Bassi NS, Ziaeian B, Yancy CW, Fonarow GC. Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol. 2020, 5:948-51. 10.1001\/jamacardio.2020.0898","journal-title":"JAMA Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen J","year":"2010","unstructured":"Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010, 1:57-92. 10.1007\/s13300-010-0006-4","journal-title":"Diabetes Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01746.x","article-title":"Active sugar transport in health and disease","volume":"261","author":"Wright EM","year":"2007","unstructured":"Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007, 261:32-43. 10.1111\/j.1365-2796.2006.01746.x","journal-title":"J Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris GL","year":"2009","unstructured":"Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009, 75:1272-7. 10.1038\/ki.2009.87","journal-title":"Kidney Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune H","year":"2005","unstructured":"Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005, 54:3427-34. 10.2337\/diabetes.54.12.3427","journal-title":"Diabetes"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon V","year":"2020","unstructured":"Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020, 16:317-36. 10.1038\/s41581-020-0256-y","journal-title":"Nat Rev Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz JR","year":"2005","unstructured":"Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005, 21:31-8. 10.1002\/dmrr.532","journal-title":"Diabetes Metab Res Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2000.7729","article-title":"T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats","volume":"49","author":"Adachi T","year":"2000","unstructured":"Adachi T, Yasuda K, Okamoto Y, et al.. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism. 2000, 49:990-5. 10.1053\/meta.2000.7729","journal-title":"Metabolism"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-26714","article-title":"Normalization of cytoplasmic calcium response in pancreatic beta-cells of spontaneously diabetic GK rat by the treatment with T-1095, a specific inhibitor of renal Na+-glucose co-transporters","volume":"34","author":"Yasuda K","year":"2002","unstructured":"Yasuda K, Okamoto Y, Nunoi K, et al.. Normalization of cytoplasmic calcium response in pancreatic beta-cells of spontaneously diabetic GK rat by the treatment with T-1095, a specific inhibitor of renal Na+-glucose co-transporters. Horm Metab Res. 2002, 34:217-21. 10.1055\/s-2002-26714","journal-title":"Horm Metab Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo LA","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015, 12:78-89. 10.1177\/1479164114561992","journal-title":"Diab Vasc Dis Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13855","article-title":"Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes","volume":"21","author":"Dekkers CC","year":"2019","unstructured":"Dekkers CC, Sj\u00f6str\u00f6m CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJ. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab. 2019, 21:2667-73. 10.1111\/dom.13855","journal-title":"Diabetes Obes Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink HJ","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013, 15:853-62. 10.1111\/dom.12127","journal-title":"Diabetes Obes Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"Skrti\u0107 M","year":"2014","unstructured":"Skrti\u0107 M, Yang GK, Perkins BA, et al.. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014, 57:2599-602. 10.1007\/s00125-014-3396-4","journal-title":"Diabetologia"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber MA","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016, 4:211-20. 10.1016\/S2213-8587(15)00417-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035588","article-title":"Twenty-four-hour ambulatory blood pressure reduction patterns after renal denervation in the SPYRAL HTN-OFF MED trial","volume":"138","author":"Kario K","year":"2018","unstructured":"Kario K, B\u00f6hm M, Mahfoud F, et al.. Twenty-four-hour ambulatory blood pressure reduction patterns after renal denervation in the SPYRAL HTN-OFF MED trial. Circulation. 2018, 138:1602-4. 10.1161\/CIRCULATIONAHA.118.035588","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308030","article-title":"Chronic heart failure and inflammation: what do we really know?","volume":"119","author":"Dick SA","year":"2016","unstructured":"Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know?. Circ Res. 2016, 119:159-76. 10.1161\/CIRCRESAHA.116.308030","journal-title":"Circ Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07307","article-title":"Inflammation in heart failure: the holy grail?","volume":"68","author":"Mehta JL","year":"2016","unstructured":"Mehta JL, Pothineni NV. Inflammation in heart failure: the holy grail?. Hypertension. 2016, 68:27-9. 10.1161\/HYPERTENSIONAHA.116.07307","journal-title":"Hypertension"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action","volume":"43","author":"Packer M","year":"2020","unstructured":"Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020, 43:508-11. 10.2337\/dci19-0074","journal-title":"Diabetes Care"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.183826","article-title":"Sodium-glucose cotransporter 2 inhibition and health benefits: the Robin Hood effect","volume":"20","author":"Kalra S","year":"2016","unstructured":"Kalra S, Jain A, Ved J, Unnikrishnan AG. Sodium-glucose cotransporter 2 inhibition and health benefits: the Robin Hood effect. Indian J Endocrinol Metab. 2016, 20:725-9. 10.4103\/2230-8210.183826","journal-title":"Indian J Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee TM","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017, 104:298-310. 10.1016\/j.freeradbiomed.2017.01.035","journal-title":"Free Radic Biol Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.08.015","article-title":"SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus","volume":"30","author":"Hess DA","year":"2019","unstructured":"Hess DA, Terenzi DC, Trac JZ, et al.. SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. Cell Metab. 2019, 30:609-13. 10.1016\/j.cmet.2019.08.015","journal-title":"Cell Metab"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0564-0","article-title":"Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study","volume":"16","author":"Shigiyama F","year":"2017","unstructured":"Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, Hirose T. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017, 16:84. 10.1186\/s12933-017-0564-0","journal-title":"Cardiovasc Diabetol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070983","article-title":"Effects of different antidiabetic medications on endothelial glycocalyx, myocardial function, and vascular function in type 2 diabetic patients: one year follow-up study","volume":"8","author":"Lambadiari V","year":"2019","unstructured":"Lambadiari V, Pavlidis G, Kousathana F, et al.. Effects of different antidiabetic medications on endothelial glycocalyx, myocardial function, and vascular function in type 2 diabetic patients: one year follow-up study. J Clin Med. 2019, 8:983. 10.3390\/jcm8070983","journal-title":"J Clin Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(00)01057-3","article-title":"Heart failure etiology affects peripheral vascular endothelial function after cardiac transplantation","volume":"37","author":"Patel AR","year":"2001","unstructured":"Patel AR, Kuvin JT, Pandian NG, et al.. Heart failure etiology affects peripheral vascular endothelial function after cardiac transplantation. J Am Coll Cardiol. 2001, 37:195-200. 10.1016\/s0735-1097(00)01057-3","journal-title":"J Am Coll Cardiol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1177\/1479164117733626","article-title":"Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis","volume":"15","author":"Gaspari T","year":"2018","unstructured":"Gaspari T, Spizzo I, Liu H, Hu Y, Simpson RW, Widdop RE, Dear AE. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. Diab Vasc Dis Res. 2018, 15:64-73. 10.1177\/1479164117733626","journal-title":"Diab Vasc Dis Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini SJ","year":"2018","unstructured":"Mancini SJ, Boyd D, Katwan OJ, et al.. Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep. 2018, 8:5276. 10.1038\/s41598-018-23420-4","journal-title":"Sci Rep"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2019.04.003","article-title":"Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin","volume":"4","author":"Juni RP","year":"2019","unstructured":"Juni RP, Kuster DW, Goebel M, et al.. Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin. JACC Basic Transl Sci. 2019, 4:575-91. 10.1016\/j.jacbts.2019.04.003","journal-title":"JACC Basic Transl Sci"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-00997-7","article-title":"Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat","volume":"19","author":"Park SH","year":"2020","unstructured":"Park SH, Farooq MA, Gaertner S, et al.. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Cardiovasc Diabetol. 2020, 19:19. 10.1186\/s12933-020-00997-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0750-8","article-title":"Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury","volume":"17","author":"Aroor AR","year":"2018","unstructured":"Aroor AR, Das NA, Carpenter AJ, et al.. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc Diabetol. 2018, 17:108. 10.1186\/s12933-018-0750-8","journal-title":"Cardiovasc Diabetol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2017.05.019","article-title":"Characterization and comparison of SGLT2 inhibitors: part 3. Effects on diabetic complications in type 2 diabetic mice","volume":"809","author":"Tahara A","year":"2017","unstructured":"Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and comparison of SGLT2 inhibitors: part 3. Effects on diabetic complications in type 2 diabetic mice. Eur J Pharmacol. 2017, 809:163-71. 10.1016\/j.ejphar.2017.05.019","journal-title":"Eur J Pharmacol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer M","year":"2017","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017, 2:1025-9. 10.1001\/jamacardio.2017.2275","journal-title":"JAMA Cardiol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG outcome study? A unifying hypothesis","volume":"39","author":"Mudaliar S","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG outcome study? A unifying hypothesis. Diabetes Care. 2016, 39:1115-22. 10.2337\/dc16-0542","journal-title":"Diabetes Care"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30314-5","article-title":"SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection","volume":"6","author":"Bell RM","year":"2018","unstructured":"Bell RM, Yellon DM. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. Lancet Diabetes Endocrinol. 2018, 6:435-7. 10.1016\/S2213-8587(17)30314-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101527","article-title":"Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1","volume":"32","author":"Behnammanesh G","year":"2020","unstructured":"Behnammanesh G, Durante GL, Khanna YP, Peyton KJ, Durante W. Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1. Redox Biol. 2020, 32:101527. 10.1016\/j.redox.2020.101527","journal-title":"Redox Biol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2019.100640","article-title":"Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice","volume":"18","author":"Takahashi H","year":"2019","unstructured":"Takahashi H, Nomiyama T, Terawaki Y, et al.. Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice. Biochem Biophys Rep. 2019, 18:100640. 10.1016\/j.bbrep.2019.100640","journal-title":"Biochem Biophys Rep"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0820-6","article-title":"SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob(-\/-) mice","volume":"18","author":"Adingupu DD","year":"2019","unstructured":"Adingupu DD, G\u00f6pel SO, Gr\u00f6nros J, et al.. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob(-\/-) mice. Cardiovasc Diabetol. 2019, 18:16. 10.1186\/s12933-019-0820-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173040","article-title":"Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice","volume":"875","author":"Ganbaatar B","year":"2020","unstructured":"Ganbaatar B, Fukuda D, Shinohara M, et al.. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Eur J Pharmacol. 2020, 875:173040. 10.1016\/j.ejphar.2020.173040","journal-title":"Eur J Pharmacol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze M","year":"2014","unstructured":"Oelze M, Kr\u00f6ller-Sch\u00f6n S, Welschof P, et al.. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 2014, 9:e112394. 10.1371\/journal.pone.0112394","journal-title":"PLoS One"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.5551\/jat.52100","article-title":"Canagliflozin prevents diabetes-induced vascular dysfunction in apoE-deficient mice","volume":"27","author":"Rahadian A","year":"2020","unstructured":"Rahadian A, Fukuda D, Salim HM, et al.. Canagliflozin prevents diabetes-induced vascular dysfunction in apoE-deficient mice. J Atheroscler Thromb. 2020, 27:1141-51. 10.5551\/jat.52100","journal-title":"J Atheroscler Thromb"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour AA","year":"2019","unstructured":"Sayour AA, Korkmaz-Ic\u00f6z S, Loganathan S, et al.. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med. 2019, 17:127. 10.1186\/s12967-019-1881-8","journal-title":"J Transl Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.05.004","article-title":"NLRP3 inflammasomes link inflammation and metabolic disease","volume":"32","author":"De Nardo D","year":"2011","unstructured":"De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011, 32:373-9. 10.1016\/j.it.2011.05.004","journal-title":"Trends Immunol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell P","year":"2010","unstructured":"Duewell P, Kono H, Rayner KJ, et al.. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010, 464:1357-61. 10.1038\/nature08938","journal-title":"Nature"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003199","article-title":"Targeting interleukin-1 in heart disease","volume":"128","author":"Van Tassell BW","year":"2013","unstructured":"Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation. 2013, 128:1910-23. 10.1161\/CIRCULATIONAHA.113.003199","journal-title":"Circulation"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo H","year":"2015","unstructured":"Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015, 21:677-87. 10.1038\/nm.3893","journal-title":"Nat Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim SR","year":"2020","unstructured":"Kim SR, Lee SG, Kim SH, et al.. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020, 11:2127. 10.1038\/s41467-020-15983-6","journal-title":"Nat Commun"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6305735","article-title":"The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic apoE-\/- mice","volume":"2016","author":"Leng W","year":"2016","unstructured":"Leng W, Ouyang X, Lei X, et al.. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic apoE-\/- mice. Mediators Inflamm. 2016, 2016:6305735. 10.1155\/2016\/6305735","journal-title":"Mediators Inflamm"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244689","article-title":"Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis","volume":"16","author":"Li CX","year":"2021","unstructured":"Li CX, Liang S, Gao L, Liu H. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS One. 2021, 16:e0244689. 10.1371\/journal.pone.0244689","journal-title":"PLoS One"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/262180-sodium-glucose-cotransporter-2-sglt2-inhibitors-and-cardiovascular-outcomes-a-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T07:57:17Z","timestamp":1720079837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/262180-sodium-glucose-cotransporter-2-sglt2-inhibitors-and-cardiovascular-outcomes-a-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":67,"URL":"https:\/\/doi.org\/10.7759\/cureus.63796","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,4]]}}}